Novartis meningitis vaccine used at 2nd US campus

February 24, 2014

(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.

Novartis said Monday that the , Bexsero, is being used at the University of California Santa Barbara until March 7 to help protect 20,000 students and staff after an .

The vaccine shot for the B strain of the meningitis bacteria is approved for use in Europe, Australia and Canada, but not yet for general use in the United States.

But the U.S. Food and Drug Administration has now approved the use of Bexsero twice in response to outbreaks at U.S. college campuses. It is the first vaccine against the B strain of meningitis.

Princeton University says almost 5,300 people got the vaccine last year in an effort to halt an outbreak there.

Explore further: Princeton vaccine reaches 90 percent of eligible

Related Stories

Princeton vaccine reaches 90 percent of eligible

December 13, 2013
Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Meningitis vaccine approved for California college

February 1, 2014
Health officials at a Southern California college will start offering a vaccine against bacterial meningitis after an outbreak in November.

Princeton starts mass meningitis B vaccinations (Update 2)

December 9, 2013
Princeton University has begun vaccinating nearly 6,000 students to try to stop an outbreak of type B meningitis in an unusual federal government-endorsed administration of a drug not generally approved for use in the United ...

Princeton U. to give students meningitis B vaccine (Update 2)

November 18, 2013
Princeton University officials decided Monday to make available a meningitis vaccine that hasn't been approved in the U.S. to stop the spread of the sometimes deadly disease on campus.

Princeton to offer meningitis B vaccine to 6,000

November 26, 2013
Princeton University says a meningitis vaccine not yet licensed for use in the U.S. will be made available on campus starting Dec. 9 to nearly 6,000 students.

EU drug regulator OKs Novartis' meningitis B shot

November 16, 2012
Europe's top drug regulator has recommended approval for the first vaccine against meningitis B, made by Novartis AG.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.